TRX-221

TRX-221 is a novel, orally bioavailable, fourth-generation, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by Therapex for the treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations. It is specifically designed to overcome resistance mediated by the C797S mutation and demonstrates activity against other clinically relevant EGFR mutations such as T790M and exon 19 deletions. Preclinical studies show that it selectively inhibits mutant EGFR while sparing wild-type EGFR, exhibits significant central nervous system (CNS) penetration, and induces tumor regression in osimertinib-resistant models. The drug is currently in Phase 1/2 clinical trials for patients with advanced or metastatic NSCLC who have progressed after prior EGFR-TKI therapies[1][2][3][4][5][6].

Other names

TRX-221TRX221TRX 221